CARBIDOPA AND LEVODOPA

Post-LOE

carbidopa and levodopa

Viatris (2)

ANDAORALTABLET, EXTENDED RELEASE

Approved

Jun 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

CARBIDOPA AND LEVODOPA (carbidopa and levodopa) by Viatris (2) is dopa decarboxylase inhibitors [moa]. Approved for the treatment of parkinson's disease, post-encephalitic parkinsonism, symptomatic parkinsonism and 2 more indications. First approved in 2019.

Drug data last refreshed 18h ago

Mechanism of Action

DOPA Decarboxylase Inhibitors

Pharmacologic Class:

Aromatic Amino Acid

Indications (5)

the treatment of Parkinson's disease post-encephalitic parkinsonism

Worked on CARBIDOPA AND LEVODOPA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

CARBIDOPA AND LEVODOPA

Mechanism of Action

Indications (5)

Clinical Trials (1)